Market Research Logo

The Worldwide Market for Anti-Infectives (Antifungals, Antibacterials and Antivirals)


Attention: There is an updated edition available for this report.

The anti-infective market is at a critical juncture. For the past 60 years, antibiotic drugs have turned bacterial infections into treatable conditions rather than the life-threatening scourges they once were. But the effectiveness of many antibiotics is waning dramatically, as more and more types of bacteria become resistant to them.

This Kalorama Information The World Market for Anti-Infectives considers the anti-infective drug market as it faces challenges with resistance and generic competition. The report focuses on three key segments of treatment:

  • Antifungals (Allylamines, Azoles,Polyene Macrolides and Other Antifungals)
  • Antibacterials (Cephalosporins, Macrolides, Penicillins, Quinolones, Sulfonamides, Tetracyclines, Carbopenems, Miscellaneous)
  • Antivirals (Nucleoside Analogs, Transcriptase Inhibitors, DNA Polymerase Inhibitors, Protease Inhibitors)
For each category and each subsegment, current market and forecast is provided. The report covers both currently marketed and late stage development products.. Revenues for each segment were generated using dollar sales for each product.

The report includes statistical information for infections by type worldwide, with special emphasis on the U.S. and Europe. As part of its coverage the report provides:

  • Overview
  • Description of Products on the Market
  • Review of Products in Late Stage Development
  • Market Estimates and Forecasts
  • Competitive Analysis of Leading Providers
  • Regional Breakdown of Antifungal, Antibacterial and Antiviral Market (US, Europe and Asia)
  • Market Share of Antifungal, Antibacterial and Antiviral Market
The information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals focused on the anti-infective industry. Telephone interviews and email correspondence were the primary method of gathering information. For the purpose of this study Kalorama Information conducted interviews with key industry officials, consultants, health care providers, and government personnel. These sources were the primary basis in gathering information specifically relating to revenue and market share data presented in this report. Specific interviews with pharmaceutical company representatives included marketing directors, division managers, and product representatives.


New York, October 1, 2009 - Drug resistance is a key public health problem and also a problem for makers of branded antibacterial products, according to the findings of a new report. Traditional antibiotics: quinolones, cephalosporins, and penicillins, have seen their market share erode due to loss of effectiveness, while at the same time they are facing heavy generic competition. Growth is flat and in some cases, sales are declining, according to healthcare market research publisher Kalorama Information’s Worldwide Market for Anti-Infectives (Antifungals, Antibacterials and Antivirals). The total world market for antibacterial drugs, which represents almost half of the anti-infectives market, is estimated at $24.5 billion for 2009, up a scant 0.7% from 2008.

Resistance is not a new concept - resistances to antimicrobials were first recognized around 1950 starting with penicillin. However, the problem is increasing at an alarming rate that far exceeds the rate at which new drugs are being discovered and brought to market. Therefore, notes Kalorama Information, preserving the effectiveness of existing antibiotics is critical to protecting public health.

“As much as half of medically prescribed antibiotics are unnecessary, which is a remnant of the misinformation that antibiotics cure all and are not harmful,” said Melissa Elder, an analyst for Kalorama Information. “In many hospitals, third generation cephalosporins are used in emergency rooms when the existence of infections has not even been established. Many such interventions are of questionable efficacy and pose an additional risk in favor of resistant bacteria.”

More than 90% of staphylococcus aureus strains are resistant to penicillin and other related antibiotics; and many are resistant even to the newer methicillin-related drugs. There is an alarming rise in the incidence of enterococci (the streptococcus that is the most common cause of hospital-acquired infections) resistant to the antibiotic vancomycin, often the last weapon for defeating these pathogens.

“Concerns over resistance have resulted in additional funding for new treatments specifically targeting resistant bacteria,” said Elder. “Although this seems to be a solution on the surface, many developers are reluctant to follow this development path.”

For more information on the anti-infectives market, see Kalorama Information’s Worldwide Market for Anti-Infectives (Antifungals, Antibacterials and Antivirals) which covers both currently marketed and late stage development products. The report includes statistical information for infections by type worldwide, with special emphasis on the U.S. and Europe, market estimates and forecasts, and competitive analysis of leading providers.

About Kalorama Information
Kalorama Information supplies the latest in independent market research in the life sciences, as well as a full range of custom research services.

  • Executive Summary
    • INTRODUCTION
    • SCOPE AND METHODOLOGY
    • TOTAL SIZE AND GROWTH OF THE MARKET
      • Table The Global Market for Anti-Infectives by Product Segment, 2006-2013
    • ISSUES AND TRENDS AFFECTING MARKET
    • LEADING COMPETITORS
  • Introduction and Industry Trends
    • OVERVIEW
      • Introduction to Pathogens
    • DEMOGRAPHICS OF THE WORLD
      • Table Estimated World Population by Age and Geographical Region, 2009 Estimated Population by Region (in millions)
    • ANTI-INFECTIVE DRUG RESISTANCE
      • Antibiotic Abuse
      • Antibiotic Use in Agriculture
      • Resistance in Select Populations
      • Measures for Reducing Resistance
    • HIV TRENDS
      • Table Worldwide HIV/AIDS Infections
      • Table Women Living with HIV/AIDS, by Region 1990 to 2007 (Percent)
      • Table AIDS Resource Needs (US$ billion), 2006-2008
      • Table Antiretroviral Access for HIV Infected Individuals by Region, 2005*
    • MANUFACTURER AND MARKETER TRENDS
      • Trends in Partnerships and Alliances
      • Developers Trends
        • Table Anti-Infective Drugs in Development by Developer
      • Trends in Rx-to-OTC Switches
        • Table Anti-infectives Ingredients Transferred from Rx-to-OTC Status by Trade Name, Distributor, and Date of OTC Approval
  • Antifungal Drugs
    • OVERVIEW
    • TYPES OF FUNGAL INFECTIONS
      • Superficial
      • Systemic
      • Fungal Infection Statistics
        • Table Estimated World and U.S. Incidence of Fungal Infections (thousands)
      • Fungal Infection Risk
        • Table World Population at Risk for Fungal Infections, Secondary to Chronic Diseases by Selected Geographical Region, 2008-2009
    • DESCRIPTION OF ANTIFUNGAL PRODUCTS
      • Systemic Antifungals
        • Table Systemic Allylamines
        • Table Systemic Azoles
        • Table Systemic Polyene Macrolides
        • Table Miscellaneous Antifungals
      • Topical Antifungals
        • Table Topical Allylamines
        • Table Topical Azoles
        • Table Topical Polyene Macrolides
        • Table Topical Miscellaneous Antifungals
    • MARKET OVERVIEW
    • TOTAL MARKET SIZE AND FORECAST
      • Table The World Market for Antifungal Drugs
      • Antifungal Market by Product Type
        • Table Antifungal Drug Market by Type 2006-2013
      • Antifungal Market by Geographical Region
        • Table The World Market for Antifungal Drugs Estimated Products Sales by Geographic Region 2006-2013
      • Market Analysis by Treated Condition
        • Table World Antifungal Market Estimated Products Sales by Infection Type Sales in Millions, 2009
    • COMPETITIVE ANALYSIS
      • Table World Market for Antifungal Drugs Estimated Revenues and Market Share of Leading Suppliers 2006-2009
      • Leading Products
        • Table World Market for Antifungal Drugs Estimated Sales of Select Products 2006-2009
  • Antibacterial Drugs
    • OVERVIEW
      • Classification of Antibacterial Organisms
        • Table Antibiotics with Difficult Penetration
      • Antimicrobial Spectrum
      • Bacterial Resistance
      • Principles of Anti-bacterial Therapy
      • Combination Therapy and Prophylactic Use
      • Bacterial Infection Statistics
        • Table Estimated World and U.S. Incidence of Bacterial Infections
      • Bacterial Infection Risk
        • Table World Population at Risk for Serious Bacterial Infections, Secondary to Chronic Diseases by Selected Geographical Region, 2008-2009
    • DESCRIPTION OF ANTIBACTERIAL PRODUCTS
      • Cephalosporins
        • Table Currently Available Cephalosporin Antibiotics (Type, Brand, and Manufacturer)
      • Macrolides
        • Table Currently Available Macrolide Antibiotics (Type, Brand, and Manufacturer)
        • Table Currently Available Penicillin Antibiotics (Type, Brand, and Manufacturer)
      • Quinolones
        • Table Currently Available Quinolone Antibiotics (Type, Brand, and Manufacturer)
        • Table Currently Available Sulfonamide Antibiotics (Type, Brand, and Manufacturer)
        • Table Currently Available Tetracycline Antibiotics (Type, Brand, and Manufacturer)
        • Table Currently Available Carbopenems (Type, Brand, and Manufacturer)
        • Table Currently Available Other Miscellaneous Antibiotics (Type, Brand, and Manufacturer)
    • MARKET OVERVIEW
    • TOTAL MARKET SIZE AND FORECAST
      • Table The World Market for Antibacterial Drugs 2006-2013
      • Antibacterial Market by Product Type
        • Table Antibacterial Drug Market by Type 2006-2013
      • Antibacterial Market by Geographical Region
        • Table The World Market for Antibacterial Drugs Estimated Products Sales by Geographic Region 2006-2013
      • Market Analysis by Treated Condition
        • Table World Antibacterial Market Estimated Products Sales by Infection Type Sales in Millions, 2009
    • COMPETITIVE ANALYSIS
      • Table World Market for Antibacterial Drugs Estimated Revenues and Market Share of Leading Suppliers 2006-2009
      • Leading Products
        • Table World Market for Antibacterial Drugs Estimated Sales of Select Products 2006-2009
  • Antiviral Drugs
    • OVERVIEW: INTRODUCTION TO VIRUSES
      • Examples of Pathogenic Viruses
    • VIRUS FUNCTION AND LIFE HISTORY
      • Replication in DNA Viruses
      • Replication of RNA Viruses
      • Replication in Retroviruses
        • Table Host Cell Receptors
    • HOST DEFENSES AGAINST VIRUSES
    • VIRAL PLOYS TO INVADE HOST CELLS AND CIRCUMVENT HOST RESPONSES
      • Invasion of Host Cells
      • Subversion of the Immune Response
      • Avoidance of Immune Detection and Attack by Killer Cells
    • HIV AND AIDS
      • Viral Infection Statistics
        • Table Estimated World and U.S. Incidence of Viral Infections Incidence (in thousands)
    • DESCRIPTION OF ANTIVIRALS PRODUCTS
      • Nucleoside Analogs, Transcriptase Inhibitors and DNA Polymerase Inhibitors
        • Table Currently Available Nucleoside Reverse Transcriptase Inhibitors (Type, Brand, and Manufacturer)
        • Table Currently Available Combination Nucleoside Reverse Transcriptase Inhibitors (Type, Brand, and Manufacturer)
        • Table Currently Available Nucleotide Analog Reverse Transcriptase Inhibitors (Type, Brand, and Manufacturer)
        • Table Currently Available Non-Nucleoside Reverse Transcriptase Inhibitors (Type, Brand, and Manufacturer)
        • Table Currently Available Combination Non-Nucleoside Reverse Transcriptase Inhibitors (Type, Brand, and Manufacturer)
        • Table Currently Available DNA Polymerase Inhibitors (Type, Brand, and Manufacturer)
      • Protease Inhibitors
        • Table Currently Available Protease Inhibitors (Type, Brand, and Manufacturer)
      • Other Antivirals
        • Table Currently Available Miscellaneous Antivirals (Type, Brand, and Manufacturer)
    • MARKET OVERVIEW
    • TOTAL MARKET SIZE AND FORECAST
      • Table The World Market for Antiviral Drugs 2006-2013
      • Antiviral Market by Product Type
        • Table Antiviral Drug Market by Type 2006-2013
      • Antiviral Market by Geographical Region
        • Table The World Market for Antiviral Drugs Estimated Products Sales by Geographic Region 2006-2013
      • Market Analysis by Treated Condition
        • Table World Antiviral Market Estimated Products Sales by Infection Type Sales in Millions, 2009
    • COMPETITIVE ANALYSIS
      • Table World Market for Antiviral Drugs Estimated Revenues and Market Share of Leading Suppliers 2006-2009
      • Leading Products
        • Table World Market for Antiviral Drugs Estimated Sales of Top Products 2006-2009
  • Market Summary
    • Table The Global Market for Anti-Infectives by Product Segment, 2006-2013
  • Corporate Profiles
    • INTRODUCTION
    • ABBOTT LABORATORIES
    • ASTRAZENECA/MEDIMMUNE
    • BAYER SCHERING PHARMA AG
    • BRISTOL-MYERS SQUIBB
    • DAIICHI SANKYO
    • GILEAD SCIENCES
    • GLAXOSMITHKLINE
    • JOHNSON & JOHNSON GROUP
    • MERCK & CO.
    • NOVARTIS
    • PFIZER
    • ROCHE
    • SCHERING-PLOUGH CORPORATION
    • WYETH
  • List of Major Providers

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report